Background: This study assessed the psychometric properties of the 10-item Connor Davidson Resilience Scale (CD-RISC-10), a self-report measure of resilience, in youth receiving treatment and/or screening positive for depression/suicidality in psychiatric outpatient settings., Methods: Data from 908 youth (age 12-20 years) were analyzed. A confirmatory factor analysis (CFA) model was fit to the data, and goodness-of-fit was assessed using indices such as the comparative fit index (CFI). Psychometric analyses were performed through the lenses of classical test theory (CTT) and item response theory (IRT). Measurement invariance of the scale was assessed by classifying the sample by depression severity. Finally, intraclass correlation coefficients (ICC) from test-retest were used to assess the reliability of the scale using data collected at baseline and one-month post-baseline., Results: The scale was unidimensional, representing a single latent trait. CFA demonstrated acceptable model fit (CFI = 0.94). CTT analyses showed good internal consistency (Cronbach's alpha 0.85) and good item discrimination (item-total correlations between 0.38 and 0.66). The scale demonstrated good test-retest reliability over a one-month period (ICC = 0.82). IRT analyses exhibited good item performance on all but the three items related to versatility, humor and persistence. These items were also deterrent to the scale having full scalar invariance., Limitations: Limitations include questionable generalizability beyond the sample and biases inherent in self-report scales., Conclusions: CD-RISC-10 has acceptable reliability and validity. However, depressive symptom severity affected selected item performance. If these findings are confirmed in other independent samples, a seven-item version of the scale may be investigated for depressed samples., Competing Interests: Declaration of competing interest Dr. Madhukar H. Trivedi has provided consulting services to Alkermes Inc., Axsome Therapeutics, Biogen MA Inc., Cerebral Inc., Circular Genomics Inc., Compass Pathfinder Limited, GH Research Limited, Heading Health Inc., Janssen, Legion Health Inc., Merck Sharp & Dohme Corp., Mind Medicine (MindMed) Inc., Merck Sharp & Dhome LLC, Naki Health, Ltd., Neurocrine Biosciences Inc., Noema Pharma AG, Orexo US Inc., Otsuka American Pharmaceutical Inc., Otsuka Canada Pharmaceutical Inc., Otsuka Pharmaceutical Development & Commercialization Inc., Praxis Precision Medicines Inc., SAGE Therapeutics, Sparian Biosciences Inc., Takeda Pharmaceutical Company Ltd., WebMD. He sits on the Scientific Advisory Board of Alto Neuroscience Inc., Cerebral Inc., Compass Pathfinder Limited, Heading Health, GreenLight VitalSign6 Inc., Legion Health Inc., Merck Sharp & Dohme Corp, Orexo US Inc., Signant Health. He holds stock in Alto Neuroscience Inc., Cerebral Inc., Circular Genomics Inc., GreenLight VitalSign6 Inc., Legion Health Inc. Additionally, he has received editorial compensation from American Psychiatric Association, and Oxford University Press. Dr. A. John Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson and Johnson (Janssen), Liva-Nova, MindStreet, Inc., Neurocrine Biosciences Inc., Otsuka-US; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Cynthia Claassen currently serves as a consultant to LivaNova, LLC and has previously consulted with the National Institute for Mental Health. She has received speaking fees from a variety of nonprofit organizations. Dr. David Farmer serves as an Executive Committee Member of the Texas Child Mental Health Care Consortium. Dr. Sarah M. Wakefield serves as an Executive Committee Member of the Texas Child Mental Health Care Consortium. Dr. Cesar A. Soutullo has worked, in the last 3 years, as a Consultant/Advisory Board member of: NeuroTech Solutions Ltd. (Israel), Limbix Health/BigHealth (US), and Inno-sphere (Germany). He has served on the Speaker bureau of Bial (Portugal), Cuquerella Medical Consulting (Spain), Medice (Germany), Rubio (Spain), and Tecnofarma (Peru). He has received Departmental (non-personal) research funds from the John S. Dunn Foundation Endowment, Texas Child Mental Health Care Consortium (Youth Depression & Suicide Research Network), The Favrot Fund, and Vivian L. Smith Foundation. He had received book royalties from Editorial Medica Panamericana. He is a full-time employee of the University of Texas (UTHealth) Houston. Mr. John R. Jeevarajan, Mr. Arrian Theodorou, Dr. Karabi Nandy, Ms. Madelyn Guerra, Dr. Nancy D. Madia, Dr. Lynnel Goodman, Dr. Abu Minhajuddin, Dr. Holli Slater, Mrs. Taryn Mayes, Ms. Amanda Rosenberg, Ms. Summer Ladd, Ms. Nic Ahumada and Ms. Sierra Jackson do not have any conflicts to declare., (Copyright © 2025 Elsevier B.V. All rights reserved.)